MAS Infrastructure and Securitised Asset Measures for Insurers: Capital Treatment and What to Do Before 18 December

MAS insurers infrastructure investment capital charges are being reconsidered again. In November 2026 MAS opened a consultation (circular ID 12/26) on a lower capital treatment under the RBC2 framework for qualifying rated infrastructure debt and for senior, investment grade securitisation tranches, and the consultation closes on 18 December 2026. Insurers and reinsurers that hold, or want to hold, these assets have a short window to test the proposals against their own portfolios and to put a considered response to MAS.

This article explains what is on the table, how it fits with the capital treatment already in force, and the practical work that finance, risk and investment teams should complete before the deadline.

What MAS has proposed

The consultation proposes enhancements to the capital treatment of two asset groups under RBC2. The first is rated infrastructure debt that meets specified credit quality and other qualifying requirements, which would attract lower capital charges than it does today. The second is senior securitisation tranches that are investment grade and meet criteria on simplicity, transparency and comparability, which would also attract lower charges.

MAS has paired the capital proposals with supporting measures. It has set aside S$30 million under the Financial Sector Development Fund for an Infrastructure Capability Development Grant for Insurers, and it is working on standardised disclosure templates, clearer assessment guidance and declarations from fund managers. The S$30 million grant is aimed at helping insurers build the in-house capability needed to originate, assess and monitor infrastructure investments, not at subsidising the investments themselves. Insurers should read the grant terms published by MAS to establish eligibility and the expenses that qualify.

The direction of travel is clear. MAS wants insurers, particularly those with long-dated liabilities, to be able to hold infrastructure and securitised assets without a capital charge that is out of proportion to the underlying risk, while keeping the controls that stop poorly understood structures from entering balance sheets.

How this builds on the existing RBC2 treatment

The consultation follows earlier work. MAS consulted in 2024 on the capital treatment of structured products and infrastructure investments, published its response, and applied the finalised treatment through the revised Notice 133 from 31 March 2026. That earlier package introduced a dedicated treatment for qualifying infrastructure investments and refined the way structured products and securitised tranches are charged, including recognition of external ratings for securitised tranches.

The November 2026 proposals should therefore be read as a further calibration, not a fresh start. Teams that already completed the work for the 31 March 2026 changes will have the most useful starting point: an asset inventory mapped to RBC2 asset risk charge categories, documented qualifying criteria assessments, and a record of which exposures were treated as infrastructure investments, structured products or ordinary credit.

For insurers that did not have material exposure in March, the consultation may change the business case. An infrastructure debt allocation that was uneconomic after the capital charge may look different if the proposed reductions are adopted. That is a strategic question for the investment committee, and it needs to be answered with numbers rather than assumptions.

Quantifying the impact on your capital position

The first task is to measure what the proposals could mean. A sound impact assessment has four parts.

First, build an asset inventory that separates current holdings and committed pipeline into rated infrastructure debt, senior securitisation tranches and everything else. Look through funds and pooled vehicles, because the characteristics that matter sit in the underlying assets and the structure, not in the wrapper.

Second, test each exposure against the qualifying criteria in the consultation paper. For infrastructure debt, that means credit quality and the other qualifying requirements. For securitisation, it means seniority, investment grade rating and the simplicity, transparency and comparability criteria. Record where evidence is missing, because gaps in documentation are likely to be the binding constraint in practice.

Third, recompute the asset risk component under the current Notice 133 treatment and under the proposed treatment, and carry the difference through to total risk requirements and the capital adequacy ratio. Show the result for the base position and under stressed conditions, including a rating downgrade scenario, since a downgrade can remove an asset from the favourable category.

Fourth, assess second-order effects: the interaction with asset-liability matching, concentration limits in the investment policy, the effect on regulatory reporting, and the impact on internal solvency targets and dividend capacity. Many insurers hold management buffers above the regulatory minimum, and a lower charge does not automatically justify releasing them.

Governance, data and operational readiness

Lower capital charges rarely arrive without higher expectations on diligence. MAS has signalled that it is developing standardised disclosure templates and fund-manager declarations. Insurers should assume that evidence supporting a qualifying classification will need to be obtained, validated and retained, and that the board and senior management remain responsible for understanding the risks of what they hold.

Practical steps include updating the investment policy and risk appetite statement to cover infrastructure and securitised assets explicitly, setting limits by structure, sector, geography and originator, and defining who signs off a qualifying assessment. The risk function should have an independent view of each classification, not only the investment team's view. Where a third-party asset manager runs the portfolio, the mandate should oblige the manager to supply the data and declarations needed for the capital assessment, on a timetable that matches regulatory reporting.

Valuation, rating monitoring and model governance also need attention. A classification that depends on an external rating needs a trigger process for rating actions. A classification that depends on structural features needs a control to detect amendments after purchase.

The same evidence should feed the ORSA. If an insurer expects to shift its asset mix because of the proposed treatment, the forward-looking capital projections and the stress and scenario testing in the ORSA should reflect the new allocation and its liquidity, credit and concentration risks. Our guidance on ORSA advisory covers how to connect investment strategy changes to the ORSA narrative.

Writing a response to the consultation

Responding is optional but valuable. MAS has changed its position after previous rounds because respondents supplied concrete data and reasoned arguments, and the final rules are shaped by what the industry says. A response that adds value tends to share these features.

It answers the questions asked in the paper, in the order asked, and states clearly whether the respondent supports each proposal. It gives evidence rather than assertion, for example the observed credit performance of the asset class, the effect on a representative portfolio, or an example of a structure that meets the spirit of the criteria but falls outside the wording. It flags operational difficulties, such as a data point that is not available from fund managers, and offers a workable alternative. It also distinguishes the views of the insurer from those of an industry body, because MAS reads both.

Allow time for internal sign-off. With a closing date of 18 December 2026, a drafting plan should start now: a first impact analysis in the next two weeks, a draft response in early December, and approval from the chief financial officer, chief risk officer and appointed actuary before submission. Confirm the exact questions, submission method and closing time against the consultation paper on the MAS website, since those details govern.

A practical timeline to the deadline

Weeks one and two: assemble the asset inventory, map holdings to current and proposed categories and identify evidence gaps. Weeks three and four: run the capital impact calculations, including stressed cases, and brief the investment committee on the strategic implications. Week five: draft the consultation response and settle any points on which you want to engage MAS directly. Week six: obtain approvals, submit, and update the ORSA and capital plan assumptions that depend on the outcome.

Whatever MAS finalises, the preparation is not wasted. The asset inventory, qualifying assessments and data agreements with managers will be needed under the current treatment and under any revised one.

Next steps

Insurers that want a structured impact assessment, support drafting a consultation response, or help aligning the investment policy and ORSA with the new treatment can speak to our team about risk-based capital advisory, and about regulatory licensing where a change in investment strategy affects supervisory engagement. Contact us before the consultation closes so that the analysis is ready in time to inform your submission.